NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $922.74 million. The enterprise value is $1.17 billion.
Important Dates
The next estimated earnings date is Monday, July 28, 2025, after market close.
| Earnings Date | Jul 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 128.69 million shares outstanding. The number of shares has increased by 0.96% in one year.
| Current Share Class | 128.69M |
| Shares Outstanding | 128.69M |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 1.23% |
| Owned by Institutions (%) | 93.45% |
| Float | 120.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 37.75 |
| PS Ratio | 1.31 |
| Forward PS | 1.19 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 26.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 121.24 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.74 |
| EV / EBITDA | 1,779.97 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.05, with a Debt / Equity ratio of 0.68.
| Current Ratio | 2.05 |
| Quick Ratio | 1.82 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 49.11 |
| Debt / FCF | n/a |
| Interest Coverage | -10.89 |
Financial Efficiency
Return on equity (ROE) is -8.57% and return on invested capital (ROIC) is -2.95%.
| Return on Equity (ROE) | -8.57% |
| Return on Assets (ROA) | -2.75% |
| Return on Invested Capital (ROIC) | -2.95% |
| Return on Capital Employed (ROCE) | -5.40% |
| Revenue Per Employee | $305,619 |
| Profits Per Employee | -$35,267 |
| Employee Count | 2,200 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 14.95 |
Taxes
| Income Tax | -1.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.01% in the last 52 weeks. The beta is 1.64, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -46.01% |
| 50-Day Moving Average | 7.86 |
| 200-Day Moving Average | 12.36 |
| Relative Strength Index (RSI) | 44.58 |
| Average Volume (20 Days) | 2,282,897 |
Short Selling Information
| Short Interest | 4.31M |
| Short Previous Month | 5.48M |
| Short % of Shares Out | 3.35% |
| Short % of Float | 3.58% |
| Short Ratio (days to cover) | 2.49 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $672.36 million and -$77.59 million in losses. Loss per share was -$0.61.
| Revenue | 672.36M |
| Gross Profit | 297.88M |
| Operating Income | -71.35M |
| Pretax Income | -83.44M |
| Net Income | -77.59M |
| EBITDA | 657,000 |
| EBIT | -71.35M |
| Loss Per Share | -$0.61 |
Full Income StatementBalance Sheet
The company has $358.08 million in cash and $604.78 million in debt, giving a net cash position of -$246.70 million or -$1.92 per share.
| Cash & Cash Equivalents | 358.08M |
| Total Debt | 604.78M |
| Net Cash | -246.70M |
| Net Cash Per Share | -$1.92 |
| Equity (Book Value) | 888.27M |
| Book Value Per Share | 6.92 |
| Working Capital | 294.24M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.61 million and capital expenditures -$39.98 million, giving a free cash flow of -$32.37 million.
| Operating Cash Flow | 7.61M |
| Capital Expenditures | -39.98M |
| Free Cash Flow | -32.37M |
| FCF Per Share | -$0.25 |
Full Cash Flow StatementMargins
Gross margin is 44.30%, with operating and profit margins of -10.61% and -11.54%.
| Gross Margin | 44.30% |
| Operating Margin | -10.61% |
| Pretax Margin | -11.70% |
| Profit Margin | -11.54% |
| EBITDA Margin | 0.10% |
| EBIT Margin | -10.61% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.96% |
| Shareholder Yield | -0.96% |
| Earnings Yield | -8.41% |
| FCF Yield | -3.51% |
Dividend DetailsAnalyst Forecast
The average price target for NeoGenomics is $13.31, which is 85.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.31 |
| Price Target Difference | 85.64% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 11.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
NeoGenomics has an Altman Z-Score of 1.75 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.75 |
| Piotroski F-Score | 5 |
